Publications
- Atezolizumab ve studii OAK naděje pro nemocné s pokročilým nemalobuněčným karcinomem plic2020 | Third Faculty of Medicine
- Longer survival in patients with NSCLC thanks to the combination of chemotherapy, immunotherapy and targeted therapy in the first line palliative treatment - results of the IMpower150 study2020 | Third Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Výborná odpověď na léčbu pembrolizumabem u nemocné se 100% expresí PD-L12019 | Third Faculty of Medicine
- First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer2017 | Central Library of Charles University
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Treatment with pembrolizumab in a patient with non-small cell lung cancer after a faecal transplantation - case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Nivolumab in a patient with NSCLC: a protracted but effective treatment full of toxicities - case report2023 | Third Faculty of Medicine
- Immunotherapy in patients with small cell lung cancer, a chance for a longer and quality life - case report2023 | Third Faculty of Medicine
Loading network view...